David Taber to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications David Taber has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
0.144
-
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. Clin Lung Cancer. 2013 May; 14(3):224-9.
Score: 0.083
-
Gefitinib plus celecoxib in chemotherapy-na?ve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. J Thorac Oncol. 2008 Apr; 3(4):374-9.
Score: 0.061